What's in a name? Use of brand versus generic drug names in United States outpatient practice

Journal of General Internal Medicine

Volumn 22, Issue 5, 2007, Pages 645-648

  Steinman, Michael A ^a   Chren, Mary Margaret ^b   Landefeld, C Seth ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Ambulatory care; Drug industry; Drug labeling; Drugs, generic; Names; Prescription fees; Prescriptions, drug

Indexed keywords

AMLODIPINE; AMLODIPINE BESYLATE; AMOXICILLIN; ARISTOCORT KENALOG; ATORVASTATIN; AZITHROMYCIN; CEFALEXIN; CELECOXIB; CETIRIZINE; CIPROFLOXACIN; CLARITHROMYCIN; ESCITALOPRAM; FEXOFENADINE; FLUOXETINE; FLUTICASONE; FLUTICASONE PROPIONATE; GENERIC DRUG; LEVOTHYROXINE; LEVOTHYROXINE SODIUM; METOPROLOL; METOPROLOL SUCCINATE; METOPROLOL TARTRATE; PREDNISONE; ROFECOXIB; SALBUTAMOL; SALBUTAMOL SULFATE; SERTRALINE; STERAPRED DS; TRIAMCINOLONE; TRIAMCINOLONE 40; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; UNITHROID; Z PACK;

ARTICLE; COMMUNITY CARE; COMPARATIVE STUDY; DRUG USE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HEALTH SURVEY; MEDICAL RECORD; NOMENCLATURE; OUTPATIENT CARE; PHYSICIAN ATTITUDE; PRESCRIPTION; STATISTICAL SIGNIFICANCE; UNITED STATES; CLASSIFICATION; DRUG COST; ECONOMICS; FEE; HUMAN; OUTPATIENT DEPARTMENT; PHARMACOKINETICS;

AMBULATORY CARE FACILITIES; DRUG COSTS; DRUGS, GENERIC; HUMANS; PRESCRIPTION FEES; TERMINOLOGY; THERAPEUTIC EQUIVALENCY; UNITED STATES;

EID: 34250338174     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-006-0074-3     Document Type: Article

References (20)

1. Haas JS, Phillips KA, Gerstenberger EP, Seger AC. Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000. Ann Intern Med. 2005;142:891-7.
2. Banahan BF, 3rd, Kolassa EM. A physician survey on generic drugs and substitution of critical dose medications. Arch Intern Med. 1997;157:2080-8.
3. Mott DA, Cline RR. Exploring generic drug use behavior: the role of prescribers and pharmacists in the opportunity for generic drug use and generic substitution. Med Care. 2002;40:662-74.
4. Suh DC. Trends of generic substitution in community pharmacies. Pharm World Sci. 1999;21:260-5.
5. National Center for Health Statistics. Public use micro-data file documentation, National Ambulatory Medical Care Survey, 2003. Hyattsville, MD: National Technical Information Service; 2005. Available at http://www.cdc.gov/ nchs/about/major/ahcd/ahcd1.htm.
6. National Center for Health Statistics. Using ultimate cluster models with NAMCS and NHAMCS public use files. Available at: http://www.cdc.gov/nchs/data/ ahcd/ultimatecluster.pdf. Accessed 19 May, 2005.
7. Mathews AW. When a drug maker creates a new pill, Uncle Sam vets name. FDA tries to avoid mix-ups, similar monikers, dupes; Bonviva becomes Boniva. Wall Street J. March 17, 2006:1.
8. Hemminki E, Enlund H, Hellevuo K, Laurila R, Turakka H. Trade names and generic names. Problems for prescribing physicians. Scand J Prim Health Care. 1984;2:84-7.
9. Bower AD, Burkett GL. Family physicians and generic drugs: a study of recognition, information sources, prescribing attitudes, and practices. J Fam Pract. 1987;24:612-6.
10. Berberich FR. Cephalosporin trade names. Pediatr Infect Dis J. 2003;22:388-9.
11. Caves R, Hurwitz M. Persuasion or information: promotion and the shares of brand name and generic pharmaceuticals. J Law Econ. 1988;31:299-320.
12. Meredith P. Bioequivalence and other unresolved issues in generic drug substitution. Clin Ther. 2003;25:2875-90.
13. Nightingale SL, Morrison JC. Generic drugs and the prescribing physician. JAMA. 1987;258:1200-4.
14. Fischer MA, Avorn J. Potential savings from increased use of generic drugs in the elderly: what the experience of Medicaid and other insurance programs means for a Medicare drug benefit. Pharmacoepidemiol Drug Saf. 2004;13:207-14.
15. Fischer MA, Avorn J. Economic consequences of underuse of generic drugs: evidence from Medicaid and implications for prescription drug benefit plans. Health Serv Res. 2003;38:1051-63.
16. Testimony of the Generic Pharmaceutical Association (GPhA) Before the Subcommittee on Health, House Committee of Energy and Commerce, May 18, 2005. Available at: http://energycommerce.house.gov/108/Hearings/05182005hearing1526/ Jaeger.pdf#search=%22generic%20substitution%20utilization%22. Accessed 23 October, 2006.
17. Congressional Budget Office. How Increased Competition from Generic Drugs Has Affected Prices and Returns in the Pharmaceutical Industry. Available at: http://www.cbo.gov/ftpdocs/6xx/doc655/pharm.pdf. Accessed 13 July, 2006.
18. Anton C, Cox AR, Ferner RE. Using trade names: sometimes it helps. Arch Intern Med. 2002;162:2636.
19. Schwab M, Oetzel C, Morike K, Jagle C, Gleiter CH, Eichelbaum M. Using trade names: a risk factor for accidental drug overdose. Arch Intern Med. 2002;162:1065-6.
20. Accreditation Council for Continuing Medical Education. Standards for Commercial Support. Available at: http://www.accme.org/dir_docs/doc_upload/ 68b2902a-fb73-44d1-8725-80a1504e520c_uploaddocument.pdf. Accessed 13 July, 2006.